Other Clinical Trial - Intravesical Ty21a for the Treatment of Patients

Status Recruiting

Clinical Trial Summary

Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) is used to prevent recurrence and/or progression. However, BCG immunotherapy is associated with significant adverse events and treatment failure may occur in 30-40% of cases, hence the necessity for alternative therapies. In an orthotopic MB49 mouse bladder cancer model, another bacterial vaccine (Ty21a/Vivotif) turned out to be more effective than BCG for inducing tumor regression and mice survival upon intravesical instillation; and potentially safer because Ty21a bacteria did not infect/persist in any mice tissues nor in human bladder explants or cell lines, in contrast to BCG. Ty21a/Vivotif has been used in the last 30 years in millions of individuals as an oral typhoid vaccine with a high safety record. In this phase I trial we will be testing the safety of intravesical administration of Ty21a and its effect on bladder immunity in non-muscle invasive bladder cancer (NMIBC) patients, for whom recommendation of BCG therapy is not mandatory.

Clinical Trial Description

Escalating doses of Ty21a/Vivotif® will be administered by the intravesical route to evaluate whether Ty21 may replace the standard BCG immunotherapy in NMIBC patients. The minimal starting dose will be instilled intravesically once a week for 4 weeks in 3 patients. If well tolerated, a 5-fold higher dose will be instilled 4-times in 3 other patients, and so on for a maximum of 4 doses to be tested. The maximal tolerated dose will then be administered to 3 new patients 6-times once a week. If 6 instillations are well tolerated, 7 additional patients will be included to receive 6 instillations with this maximal tolerated dose. ;

Study Design

Related Conditions & MeSH terms

Non Muscle Invasive Bladder Cancer
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT03421236
Study type	Interventional
Source	University of Lausanne Hospitals
Contact	denise N Haefliger, PhD
Phone	+41213144081
Email	dnardell@hospvd.ch
Status	Recruiting
Phase	Phase 1
Start date	February 18, 2018
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06020807` - Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
Recruiting	`NCT04452591` - Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Phase 3
Recruiting	`NCT06167356` - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Withdrawn	`NCT01799499` - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)	N/A
Completed	`NCT02343614` - Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer	Phase 2
Recruiting	`NCT05945108` - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting	`NCT06287541` - The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection	N/A
Recruiting	`NCT06181266` - A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer	Phase 1
Terminated	`NCT02982395` - Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC	Phase 3
Completed	`NCT06205277` - Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
Completed	`NCT01731652` - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer	Phase 2
Active, not recruiting	`NCT04387461` - Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin	Phase 2
Recruiting	`NCT06111235` - A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Phase 3
Recruiting	`NCT02895620` - Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC	N/A
Completed	`NCT01004211` - Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging	N/A
Active, not recruiting	`NCT05981131` - Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms